Weight Management with Oral GLP-1 Treatments

Using our enteric coating technology, Altanine is advancing oral delivery systems designed to improve the bioavailability and patient convenience of GLP-1–based medications.

Yes. GLP-1–based medications, including semaglutide and liraglutide, are used for managing type 2 diabetes and supporting weight management in patients with obesity or overweight-related conditions.

GLP-1–based treatments typically begin to improve blood sugar control within the first few weeks of therapy, with full effects on glycemic balance and weight management developing over time.

Semaglutide is a medication primarily used to treat type 2 diabetes and aid in weight management. It belongs to a class of drugs known as GLP-1 (glucagon-like peptide-1) receptor agonists, which help regulate blood sugar levels and reduce appetite. Semaglutide improves glycemic control and supports weight loss in patients.

Liraglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist used to help manage type 2 diabetes and support chronic weight management. It enhances insulin secretion, slows gastric emptying, and reduces appetite, helping improve blood glucose control and support gradual weight loss.

Tirzepatide is a dual GIP and GLP-1 receptor agonist that improves blood sugar control and supports significant weight reduction. By activating two incretin hormone pathways, it enhances insulin sensitivity and regulates appetite.

Dulaglutide is a once-weekly GLP-1 receptor agonist prescribed for type 2 diabetes. It stimulates insulin release in response to meals and decreases glucagon secretion, helping maintain stable blood sugar levels and offering cardiovascular benefits.